- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Esaote launches AU5 Harmonic scanner
Italian vendor Esaote released its AU5 Harmonic ultrasound scanner at the Congress of the World Federation for Ultrasound Medicine and Biology in Buenos Aires, Argentina, earlier this month. In its standard configuration, the multidisciplinary scanner
Italian vendor Esaote released its AU5 Harmonic ultrasound scanner at the Congress of the World Federation for Ultrasound Medicine and Biology in Buenos Aires, Argentina, earlier this month. In its standard configuration, the multidisciplinary scanner allows users to optimize ultrasound studies via the use of a contrast agent, according to the Genoa-based company.
AU5 includes both color and power Doppler functions and can accommodate specialized probes, such as high-frequency probes up to 20 MHz, for superficial imaging as well as transducers targeted to intraoperative and surgical applications. It also offers networking capabilities that allow the user to send images and patient data through both a local area network and the Internet, according to Esaote.
The scanner appears to be the enhanced version of Esaote's AU4 system that the vendor has been working on with Bracco (SCAN 7/17/96). According to Esaote, the scanner's dedicated hardware and software that can utilize the second-harmonic imaging method are the first results of an ultrasound contrast research program established by Esaote in cooperation with Bracco.
AU5 is available for sale in international markets except for the U.S., where Esaote expects to be able to sell the scanner next year. The scanner is CE marked, according to Esaote.
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
